Pharmacoeconomic assessment of dual bronchodilation therapy in patients with COPD

This study was aimed at clinical and economic assessment of feasibility of inclusion glycopyrronium bromide/indacaterol fixed combination in the State Program for providing necessary drugs to patients. Methods. This retrospective study was based on previously published clinical data. Change of economic burden was assessed using budget impact analysis. Cost-efficacy was assessed using cost minimization analysis and lost opportunities analysis. Results. Switching COPD patients from free combination of long-acting bronchodilators (LABD) to glycopyrronium bromide/indacaterol fixed combination has led to 20.44% decrease in the economic burden. The 3-year cost reduction of COPD therapy has reached RUB 2,416 bln. Conclusion. The results demonstrated higher cost-efficacy of glycopyrronium bromide/indacaterol fixed combination compared to the standard therapy of COPD. Inclusion of glycopyrronium bromide/indacaterol combination into the State Program for providing necessary drugs to COPD patients could be rational and ecomonically feasible.

COPD, long-acting bronchodilators, indacaterol, tiotropium bromide, glycopyrronium bromide/indacaterol, economic burden, budget impact analysis on the

1. Sinopal'nikov A.I., Zaytsev A.A. Antibacterial therapy of acute exacerbation of chronic bronchitis/chronic obstructive pulmonary disease: key points. Meditsinskiy sovet. 2017; 18: 14–20 (in Russian). DOI: 10.21518/2079-701X-2017-18-14-20.

2. Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65 (6): 473–479. DOI: 10.1136/thx.2009.125435.

3. Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.

4. Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI: 10.1016/S2213-2600(13)70052-3.

5. Frampton J.E. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488. DOI: 10.1007/s40265-014-0194-8.

6. Banerji D., Fogel R., Patalano F. Indacaterol/glycopyrronium: a dual bronchodilator for COPD. Drug Discov. Today. 2018; 23 (1): 196–203. DOI: 10.1016/j.drudis.2017.10.015.

7. Zyryanov S.K., Frolov M.Yu., Belevskiy A.S. Clinical efficacy and cost-effectiveness of indacaterol / glycopyrronium bromide fixed combination in chronic obstructive pulmonary disease. Prakticheskaya pul'monologiya. 2016; (4): 76–84 (in Russian).

8. Donohue J. F., Betts K.A., Du E.X. et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Intern. J. COPD. 2017: 12: 367–381. DOI: 10.2147/COPD.S119908.

9. Keininger D.L., Price D., Viswanad B. et al. Real-life experience of COPD patients on ease and accuracy of inhaler use: the REAL survey. J. Thorac. Dis. 2016; 8 (Suppl. 5): AB036. DOI: 10.21037/jtd.2016.s036.

10. Molimard M., Raherison C., Lignot S. et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur. Respir. J. 2017; 49 (2): 1601794. DOI: 10.1183/13993003.01794-2016